Sernova Biotherapeutics Inc (TSX:SVA)

Sernova Biotherapeutics Income Statement

Financials in millions CAD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 31, 2026	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021
Other Operating Expenses	12.34	15.02	31.66	40.5	24.75	6.94
Total Operating Expenses	12.34	15.02	31.66	40.5	24.75	6.94
Operating Income	-12.34	-15.02	-31.66	-40.5	-24.75	-6.94
Interest Income	0	0.03	0.39	1.5	0.58	0.07
Interest Expense	-1	-0.75	-0.59	-0.03	-0.12	-0.06
Other Non-Operating Income (Expense)	0.88	0.02	-0.32	0.04	-0.13	-0.04
Total Non-Operating Income (Expense)	-0.11	-0.71	-0.52	1.5	0.33	-0.03
Pretax Income	-12.45	-15.73	-32.19	-39	-24.42	-6.97
Provision for Income Taxes	0	0.08	0.01	-	-	-
Net Income	-12.38	-15.74	-32.19	-39	-24.42	-6.97
Net Income to Common	-12.38	-15.74	-32.19	-39	-24.42	-6.97
Shares Outstanding (Basic)	331	328	307	303	274	246
Shares Outstanding (Diluted)	331	328	307	303	274	246
Shares Change (YoY)	5.60%	6.95%	1.19%	10.87%	11.43%	24.45%
EPS (Basic)	0.04	0.05	0.10	0.13	0.09	0.03
EPS (Diluted)	0.04	0.05	0.10	0.13	0.09	0.03
EPS Growth	-50.00%	-50.00%	-23.08%	44.44%	200.00%	-
Shares Outstanding	342.08	332.86	325.33	303.33	303.33	261.13
Free Cash Flow	-7.13	-10.91	-18.9	-30.44	-14.75	-6.86
Free Cash Flow Per Share	-0.02	-0.03	-0.06	-0.10	-0.05	-0.03
EBITDA	-12.04	-14.68	-31.12	-40.06	-24.31	-6.67
EBIT	-12.34	-15.02	-31.66	-40.5	-24.75	-6.94
Effective Tax Rate	-0.01%	-0.50%	-0.02%	0.00%	0.00%	0.00%

Updated Mar 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.